1: Frezoulis P, Harper A. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review. Vet Comp Oncol. 2022 Jun;20(2):362-371. doi: 10.1111/vco.12799. Epub 2022 Jan 17. 18(4):519-527. doi: 10.1111/vco.12571. Epub 2020 Feb 13. 19(2):185-193. doi: 10.1177/1098612X15622237. Epub 2016 Jul 9. 4: Sheppard-Olivares S, Bello NM, Johannes CM, Hocker SE, Biller B, Husbands B, Snyder E, McMillan M, McKee T, Wouda RM. Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019). Vet Rec Open. 2022 Jan 20;9(1):e27. doi: 10.1002/vro2.27. 5: Berger EP, Johannes CM, Post GS, Rothchild G, Shiu KB, Wetzel S, Fox LE. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia. J Feline Med Surg. 2018 Feb;20(2):95-102. doi: 10.1177/1098612X17695898. Epub 2017 Mar 1.
合成参考文献
参考文献:10.1186/1746-6148-10-105 摘要:Halsey CH, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. BMC Veterinary Research. 2014 May 06;10(1):105. doi: 10.1186/1746-6148-10-105. 参考文献:10.1111/vco.12177 摘要:Lewis RS, Fidel J, Dassanayake S, Court MH, Burke NS, Mealey KL. Comparison of chemotherapeutic drug resistance in cells transfected with canineABCG2or felineABCG2. Vet Comparative Oncology. 2015 Oct 14;15(2):411–20. doi: 10.1111/vco.12177. 参考文献:10.1111/vde.12422 摘要:Cavalcanti JVJ, Hasbach A, Barnes K, Dange RB, Patterson J, Saavedra PV. Skin depigmentation associated with toceranib phosphate in a dog. Vet Dermatol. 2017 Aug;28(4):400–e95. doi: 10.1111/vde.12422.